Abstract: A battery arrangement (100) and a method for operating a battery arrangement are provided. The battery arrangement comprises an identity reader (115) and a battery system (120). The identity reader is configured to obtain an identity from an identifier (110) fastened to an immobile object (150). The battery system is distinct from the immobile object. The battery arrangement is configured to disable at least part of the battery system in response to the identity reader being unable to obtain the identity. The method comprises monitoring a sensor for obtaining an identity from an identifier fastened to an immobile object and disabling at least part of the battery system in response to failure to obtain the identity. Accordingly, an anti-theft solution for a battery arrangement is provided.

Abstract: A battery module comprises charging for connecting the battery module to a power source, a battery cell arrangement, and a DC-to-DC converter. A first terminal of the battery cell arrangement is connected to a first charging terminal. An input terminal of the converter is connected to the second terminal of the battery cell arrangement and another input terminal of the converter is connected to the second charging terminal. An output terminal of the converter is connected to the first terminal of the battery cell arrangement. The converter converts an input voltage (U3) received at its input terminals to an output voltage (U2) at the output terminal of the converter. The output voltage is higher than the input voltage. The battery module may for example be employed as a backup power source in a mobile communication base station. A switch arrangement may for example allow the converter to be bypassed.

Abstract: This invention relates to methods and systems for generating a safe and effective oral smallpox vaccine for humans using a genetically defective strain of vaccinia virus to confer immunity following oral delivery of the vaccine. This invention is one that expands on current use of vaccinia virus propagation developed for gene therapy applications, and pharmaceuticals and nutraceuticals packaging and formulation technologies. The vaccine invention can be delivered as a live virus with the ability to express viral proteins but unable to achieve complete, lytic virus replication, or it may be derived from such a virus, contain additional immunogens, or be delivered as viral antigens. Furthermore, the invention establishes innovative methods for formulation and packaging and for preclinical testing of the vaccine invention for safety, efficacy and potency with the use of human intestinal and other test cells and diagnostic test systems and kits.

Abstract: An improved device, in the form of a container, for propagating explant cultures under sterile conditions while facilitating gas exchange with an outside environment, methods for employing the device, a process of manufacture to produce the device, a mold for use as part of the process of manufacture, and an apparatus for conducting the process of manufacture employing the mold.

Abstract: A method is provided for making transgenic animals by transferring DNA into embryo by subjecting the mixture of the DNA to be transferred and the embryo to an electric discharge.